Comparison of psychosocial adaptation and sexual function of survivors of advanced hodgkin disease treated by MOPP, ABVD, or MOPP alternating with ABVD Journal Article


Authors: Kornblith, A. B.; Anderson, J.; Cella, D. F.; Tross, S.; Zuckerman, E.; Cherin, E.; Henderson, E. S.; Canellos, G. P.; Kosty, M. P.; Cooper, M. R.; Weiss, R. B.; Gottlieb, A.; Holland, J. C.
Article Title: Comparison of psychosocial adaptation and sexual function of survivors of advanced hodgkin disease treated by MOPP, ABVD, or MOPP alternating with ABVD
Abstract: Background. Survivors of advanced Hodgkin disease, who were assigned randomly to treatment by mechlorethamine, vincristine, procarbazine, and prednisone (MOPP); doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD); or MOPP alternating with ABVD in a clinical trial of the Cancer and Leukemia Group B (protocol 8251), were compared in terms of their psychosocial adaptation and psychosexual function an average of 2.2 years after completion of treatment (range, 1‐5 years). The study was undertaken to determine if there were differences among treatments in these functional areas as a consequence of differential long‐term gonadal damage in the three regimens. Methods. Ninety‐three disease‐free survivors of advanced Hodgkin disease (56 men and 37 women) were studied (a minimum of 1 year after completion of treatment) by an interview conducted over the telephone. Standardized measures were used to assess their psychologic, sexual, family, and vocational functioning, including the following tests: the Psychosocial Adjustment to Illness Scale‐Self Report, the Brief Symptom Inventory, the Profile of Mood States, and the Impact of Event Scale. Results. Contrary to expectation, no statistically significant differences in survivors' psychosocial adaptation or psychosexual function were found by treatment arm. Infertility (based on survivors' reports of medical test results and perceptions) and lower income 1 year before the diagnosis of cancer were significant predictors of poorer adjustment. Most survivors reported a range of problems that they attributed to having had cancer: 35%, proven or perceived infertility; 24%, sexual problems; 31%, health and life insurance problems; 26%, a negative socioeconomic effect; and 51%, conditioned nausea, associated with visual or olfactory reminders of chemotherapy. Conclusions. No significant long‐term advantage in psychosocial adaptation or psychosexual function was found for survivors of Hodgkin disease treated by the less gonadally toxic ABVD regimen 1 to 5 years after completion of treatment. Copyright © 1992 American Cancer Society
Keywords: adult; cancer survival; major clinical study; prednisone; doxorubicin; cancer combination chemotherapy; comparative study; dacarbazine; antineoplastic combined chemotherapy protocols; vincristine; chlormethine; procarbazine; vinblastine; hodgkin disease; infertility; gonadal disease; adaptation, psychological; bleomycin; phase 3 clinical trial; sexual function; socioeconomics; self assessment (psychology); family; middle age; cancer survivors; sexual dysfunctions, psychological; psychosocial environment; social adaptation; social adjustment; job performance; abvd; mopp; psychosexual; psychological tests; psychosocial adaptation; mechlorethamine; human; male; female; priority journal; article; support, u.s. gov't, p.h.s.
Journal Title: Cancer
Volume: 70
Issue: 10
ISSN: 0008-543X
Publisher: Wiley Blackwell  
Date Published: 1992-11-15
Start Page: 2508
End Page: 2516
Language: English
DOI: 10.1002/1097-0142(19921115)70:10<2508::Aid-cncr2820701020>3.0.Co;2-v
PUBMED: 1384949
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 30 July 2019 -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Jimmie C B Holland
    304 Holland